Search global stocks & ETFs...Ctrl K
Learn Mode
Aurinia Pharmaceuticals IncAUPH
$15.96
$0.02 (0.125%)
$16.12
$0.16 (1.015%)
AUPH
Stock Profile
07-30
Recommended Metric
Score Card
Explore Scores Tab
4.30
Very Good
Valuation Score
Key Score
5.00
Very Good
Management
5.00
Very Good
Growth
5.00
Very Good
Profitability
1.00
Very Bad
Fin. Health
2.00
Bad
Dividends
--
--
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending Jun 28, 2027
Current
$15.96
Baseline
High
$22.05
▲
38.16%
Avg
$17.34
▲
8.65%
Low
$15.15
▼
-5.08%
Analyst Ratings based on 13 Analysts
Strong Buy
323%
Buy
646%
Hold
431%
Sell
000%
Strong Sell
000%
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The firm sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.Read More